Magnetic collection of ctxii from small volumes of synovial fluid  by Yarmola, E.G. et al.
Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S73as serological markers reﬂecting tissue turnover of type I, II, III collagen
and autoimmunity by citrullinated vimentin.
Methods: The C4P-003 study included 204 symptomatic (VASpain >
10) knee OA patients (KL 1 to 4) and 71 subjects of same age and gender
distribution, with no signs of knee OA (VASpain<10, KL ¼ 0). Mean age
was 64.5 (42-80), BMI was 28.1 (18.5- 47.3) and there was 49 % female.
Following clinical outcomes were monitored; VASpain (0-10 cm),
radiographic assessment of both knees, OA functionality questionnaires
(WOMAC, EQ5D, LEQ), standard blood works (e.g. CRP), and vitals (BMI,
smoking, blood pressure). Serological biomarkers were measured by
competitive ELISA: MMP-mediated degradation fragments of type I, II
and III collagen; C1M (soft connective tissue), C2M (cartilage degrada-
tion) and C3M (ﬁbrogenesis), and MMP-generated fragment of cit-
rullinated vimentin (VICM). C2M and C1M were used as classiﬁcation
variables setting cut-offs at the medians (N ¼ 275); at 258 pmol/L and
40 nmol/L, respectively. Subjects were subdivided into quartiles: Q1,
low C2M/low C1M; Q2, low C2M/high C1M; Q3, high C2M/low C1M; Q4,
high C2M/high C1M. Kruskal-Wallis test used to compare the quartiles.
Results: Serum C1M and C2M were independent co-variables (rho ¼
0.08). When separating the subjects into quartiles the age, gender and
BMI distribution remained the same. WOMAC pain and function were
signiﬁcantly higher (p0.1). CRP as well as C3M levels were signiﬁcantly
higher (p<0.00001) in those patients with a high C1M level (Q2&Q4).
There was a tendency (p ¼ 0.079) towards lower level of VICM in
patients with both low level of C2M and C1M (Q1), as summarized in
the ﬁgure.
Conclusions: High soft tissue degradation was associated with
inﬂammation and ﬁbrosis, as validated for other disease pathologies.
However, patients with a high level of cartilage degradation, but with
low inﬂammation and ﬁbrosis experienced lower pain and better
function of their knee, indicating that cartilage degradation in itself is
independent of symptomatic OA. Patients with low cartilage and soft
tissue degradation had a signiﬁcantly lower level of citrullinated anti-
gens, reﬂecting a phenotype without an auto-immune component.
Interestingly, KL score was not associated with any of the groups.115
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Purpose: There is a great medical need for regeneration of damaged
cartilage for the beneﬁt of OA patients. Consequently, there is an intense
search for safe anabolic treatment for articular cartilage. However, there
is a lack of tools to investigate the action of anabolic pathways in
chondrocytes. This constitutes a need for biomarkers, which can
quantify cartilage formation. The aim of the study was to develop an
ELISA (ProC2), which is speciﬁc for the beta splice variant of the N-
terminal type II procollagen (P2BNP). This splice variant is expressed in
healthy cartilage, whereas the expression of the 69 amino acids longeralpha splice variant (P2ANP) is associated with embryogenesis and
cartilage pathologies. We hypothesized that the beta splice variant is
the form that is needed for regeneration/repair of mature cartilage, thus
the effect of anabolic factors should result in the release of P2BNP.
Furthermore we investigated whether the P2BNP assay was able to
detect changes in collagen formation in an ex vivo bovine full-depth
cartilage explants model (BEX).
Methods: A competitive ELISA speciﬁcally measuring P2BNP was
developed applying amonoclonal antibody raised inmouse recognizing
the N-terminus of the N-terminal propeptide of collagen type II. The
assay was technically validated. The range of the assay was 1.25-
37nmol/L (intra-assay CV 6.87%, inter-assay CV 8.92%). Tests of linearity
and analytic sensitivity, speciﬁcity, and stability of human amniotic
ﬂuid, fetal bovine serum (FBS) and human serum from women over 60
years were evaluated in the assay. After coating streptavidin plates with
biotin-QDVRQPG samples were added together with the antibody. The
plates were thereafter incubated with EnVision. Tetramethyl benzini-
dine (TMB) was added. The TMB reactionwas stopped by adding H2SO4
and measured at 450 nm with 650 nm as the reference.
The BEX explants (approx. :12mg) were isolated from the femur condyle
and cultured for 3 weeks in serum free DMEM/F12 medium with 3
weekly changes. Supernatant was collected. Following anabolic factors
were applied: transforming growth factor (TGF)-b, ﬁbroblastic growth
factor (FGF)-2, and insulin like growth factor (IGF)-1 each in concen-
trations of 100, 10, 1, 0.1, 0.001ng/ml. Data are shown as mean [95%-CI]
or (SD). Two tailed Mann Whitney test was used to compare bars with
vehicle. The viability of the explants was tested by Alamar blue prior to
cytokine stimulation and at termination.
Results: The ProC2 assay was sensitive and speciﬁc for human/bovine
N-terminal of the procollagen type II seen by a 100% inhibition of the
signal with 150nmol/L selection peptide: peptides with the corre-
sponding rat/mouse or the human alpha splice variant sequence could
not displace the signal. High levels of P2BNP was quantiﬁed in human
amniotic ﬂuid (163-187,7nmol/L) and FBS (851-901nmol/L) and showed
excellent linearity (dilution range 1:2-1:64 and 1:20-1:160 with 100%
(SD 7.6) recovery). In contrast, serum P2BNP levels in the elderly
women were below the lower detection limit. No signiﬁcant matrix
effect was observed in serum or conditioned medium. In the medium
from BEX, it was found that TGF-b and IGF-1 signiﬁcantly induced
secretion of P2BNP in a dose-dependent manner compared to the
untreated (ﬁgure). This association was not seen when explants were
stimulated by FGF-2.
Conclusion:To our knowledge this is the ﬁrst assay which is able to
evaluate P2BNP excretion. The ProC2 assay seems to be a promising and
novel marker of collagen type II formation. The assay was both sensitive
and speciﬁc for the beta-splice variant of collagen type II. In addition the
assay was able to differentiate between P2BNP level in supernatant of
BEX explants stimulated by either TGF-b or IGF-1 compared to
untreated.116
MAGNETIC COLLECTION OF CTXII FROM SMALL VOLUMES OF
SYNOVIAL FLUID
E.G. Yarmola, Y. Shah, K.D. Allen. Univ. of Florida, Gainesville, FL, USA
Purpose: Molecular biomarker analysis in urine and serum has dem-
onstrated potential to diagnose osteoarthritis (OA) at an earlier stage
than traditional radiographic scans. Recent studies in horses suggest
biomarker analysis in synovial ﬂuid may detect OA changes prior to the
serum and urine analysis of the same biomarker. Clinically and in large
animals, synovial ﬂuid can be acquired through joint aspiration; how-
ever, the development of OA biomarkers in small animal models is
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ration. Lavage and ﬂuid wicking can acquire synovial ﬂuid samples in
small animals; however, both techniques are primarily used following
animal euthanasia, making longitudinal OA biomarker analysis practi-
cally impossible in a small animal model.
Our group has developed a magnetic nanoparticle-based technology to
collect OA biomarkers from synovial ﬂuid (Figure 1). First, an antibody
against an OA biomarker is conjugated to the surface of magnetic par-
ticles. Antibody-conjugated particles are used to bind biomarkers in
synovial ﬂuid. Then, a magnetic probe is used to collect a percentage of
the particle-biomarker conjugate from synovial ﬂuid. Biomarker is
released from particles using heat, then particles are released from the
probe using sonication and a magnetic plate. Using a biomarker col-
lected per particle ratio, the amount of biomarker in synovial ﬂuid can
be estimated. The purpose of this study is to assess the sensitivity of
magnetic collection relative to ELISAs conducted on small volume
synovial ﬂuid samples.
Methods: Antibodies against a widely-investigated OA biomarker, C-
telopeptide of type II collagen (CTXII, Immunodiagnostic Systems),
were conjugated to 1-2 mm diameter polystyrene particles containing
10-20 nm diameter superparamagnetic iron oxide nanoparticles
(SPIONS) in the particle core (10% SPIONS by volume). The effect of
synovial ﬂuid viscosity on the magnetic collection technique was
investigated by artiﬁcially degenerating synovial ﬂuid with hyalur-
onidase (0.01 mg/ml for 4.5 hr at room temperature). In particular, 1
billion particles with approximately 400 antibody molecules per par-
ticle were mixed with 400 mL of hyaluronidase-treated or untreated
bovine synovial ﬂuid. To investigate the antibody-CTXII binding kinet-
ics, 50 mL aliquots were acquired for analysis at approximately 1, 2.5, 5,
10, 20, and 40 min. In addition, magnetic particles with approximately
800 antibody molecules per particle were mixed with either hyalur-
onidase-treated or untreated bovine synovial ﬂuid (SF), subjected to
constant gentle mixing for 1 h, then divided into 25 mL samples (97
million particles per sample). In these samples, magnetic needles were
inserted for varying time intervals and the amount of collected particles
was determined by ﬂuorescence.
Results: Synovial ﬂuid viscosity had minor only effects on antibody-
biomarker binding kinetics (Figure 2), indicating the ratio of biomarker
to antibody (or biomarker per particle) could be used to estimate the
initial biomarker amount in a sample as long as magnetic collectionwas
conducted after a dynamic equilibrium was been established. Synovial
ﬂuid viscosity did have marked effects on the collection efﬁciency of
magnetic particles in synovial ﬂuid (Figure 3). However, since magnetic
collection occurred only after the antibody and biomarker reached a
dynamic binding equilibrium, the ratio of biomarker to antibody was
able to estimate the initial concentration of CTXII in a synovial ﬂuid
sample with similar precious to an ELISA conducted on an aliquot of the
same synovial ﬂuid sample (Figure 4).
Conclusions: In this work, critical variables for magnetic collection of
CTXII are described, thereby demonstrating the potential to magneti-
cally collect OA biomarkers in synovial ﬂuid volumes similar to that of a
rat knee. Future work will focus on demonstrating the technique in an
intact rat knee, where joint geometry is far more complex than the
present in vitro studies. Nonetheless, these data demonstrate an in vitro
proof-of-concept for magnetic collection of OA biomarkers.117
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Purpose: Intermittent knee pain is a prevalent complaint in themiddle-
aged population but its signiﬁcance is poorly understood in the absence
of deﬁnitive structural changes. Increased levels of cartilage oligomeric
matrix protein (COMP), a potential prognostic biomarker in early knee
OA, have been associated with risk of incident radiographic knee OA. In
this study, we looked at the cross-sectional association of serum COMP
levels and self-reported knee pain in middle-aged UK females.
Methods: We looked at 724 subjects from the Chingford Cohort Lon-
gitudinal Study who had serum levels of COMP measured at year 2 and
3, and data on self-reported knee pain at year 3. Knee pain was deﬁned
as ‘any knee pain’ if it was present on any number of days in the pre-
ceding month in either knee and ‘pain on most days’ if it was present in
either knee on most days in the preceding month. COMP levels were
categorised into quintiles. A logistic regression model was utilised to
investigate associations between the presence of the knee pain at year 3
and serum COMP levels.
Results: Mean age was 55 years (SD þ/- 5.9; Range 46-68), Mean BMI
was 25.3 (SD þ/- 4; Range 17-47). 205 out of 724 subjects reported ‘any
knee pain’ in the last month, and 80 reported ’pain on most days’ of the
preceding month. The highest COMP quintile (levels above 12.63 U/L),
compared to the lowest, was signiﬁcantly associated with ‘any knee
pain’ in the last month (OR 1.92, 95% CI 1.09 – 3.23). This association
remained signiﬁcant after adjusting for age and vitamin D levels (OR
1.89, 95% CI 1.14 – 3.27), but not after adjustment for BMI (OR 0.7, 95%CI
0.3 – 1.52).
Conclusions: Higher levels of serum COMP are associated with ‘any
knee pain’, but not with reporting knee ‘pain on most days’ in the
preceding month. High COMP levels are associated with intra-articular
joint changes within synovium, cartilage and ligaments. Considering
that inﬂamed synovium is a signiﬁcant pain generator, episodic knee
pain associated with high COMP levels may reﬂect low-grade synovial
inﬂammation.
